



10745 Westside Way, Suite 200  
Alpharetta, GA 30009  
Tel: +1 (844) 884 5367  
Email: [info@vtivision.com](mailto:info@vtivision.com)  
[www.vtvision.com](http://www.vtvision.com)

[www.vtvisioninvestors.com](http://www.vtvisioninvestors.com) (for investors)

## ASX announcement

# Completion of Security Purchase Plan

**Atlanta, Georgia, USA, 12 September 2018:** Visioneering Technologies, Inc. (ASX: VTI), a U.S.-based medical device company (**Visioneering** or **Company**) engaged in the design, manufacture, sale and distribution of its proprietary NaturalVue® Multifocal 1 Day (NaturalVue MF) Contact Lenses, today announces that its Security Purchase Plan (**SPP**), described in the SPP booklet released to the ASX on 22 August 2018, closed on 5 September 2018 and raised A\$344,399.04.

A total of 1,913,328 new CHESS Depository Interests (**CDIs**) have been issued today at an issue price of A\$0.18 per CDI. Holding statements are scheduled to be despatched tomorrow, 13 September 2018.

- ENDS -

**For more information, please contact:**

| <b>Company</b>  | <b>Investor and media relations</b>  |
|---|--|
| Stephen Snowdy<br>CEO, Visioneering Technologies, Inc.<br>Email: <a href="mailto:ssnowdy@vtivision.com">ssnowdy@vtivision.com</a> | Kyahn Williamson<br>WE Buchan<br>Tel: +61 (3) 9866 4722<br>Email: <a href="mailto:kwilliamson@buchanwe.com.au">kwilliamson@buchanwe.com.au</a> |

### **About VTI:**

Visioneering Technologies, Inc. (**VTI**) is a US-based medical device company primarily engaged in the design, manufacture, sale and distribution of a revolutionary new contact lens: the NaturalVue® Multifocal (MF) contact lens. The NaturalVue MF contact lens employs VTI's Neurofocus Optics® technology, which was developed, refined and tested over many years. The characteristics of the NaturalVue MF contact lens allow it to be used in two of the largest eye-care markets globally: adults with presbyopia (age-related difficulty in seeing close objects) and children with myopia (near-sightedness, or difficulty seeing distant objects).

NaturalVue lenses were cleared by the FDA in late 2014 and received the CE Mark in early 2018, and VTI recently commenced its US market expansion for NaturalVue MF contact lenses, following a successful pilot US market launch in 2015 and 2016. VTI also sells and plans additional contact lens products.

### **Foreign ownership restrictions:**

VTI's CHESS Depository Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

**Forward-looking statements:**

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, U.S. commercial market acceptance and U.S. sales of our product as well as, our expectations with respect to our ability to develop and commercialize new products. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Except as required by law, VTI does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. VTI may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

MKTG-VTI-ASX r1